 |  |  |  |  |  |
| Copyright 2006-2010 Abiant, Inc. |
| Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030 |
| New and Events... |
Abiant News
Abiant Selected to Present at 2009 International Conference on Alzheimer's
Disease
Deerfield, ILLINOIS - - May 26, 2009 - - Abiant has been selected present work co-authored with
members of the New York University School of Medicine at the 2009 International Conference on
Alzheimer's Disease (ICAD). The presentation, titled "Hippocampal Glucose Metabolism Predicts
Cognitive Decline and Correlates to Disease Progression in the ADNI Population", is focused on the
results of analyses performed using imaging of glucose metabolism on participants in the
Alzheimers Disease Neuroimaging Initiative (ADNI).
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and
premier conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference
will take place from July 11 - 16 in Vienna, Austria.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
Disease
Deerfield, ILLINOIS - - May 26, 2009 - - Abiant has been selected present work co-authored with
members of the New York University School of Medicine at the 2009 International Conference on
Alzheimer's Disease (ICAD). The presentation, titled "Hippocampal Glucose Metabolism Predicts
Cognitive Decline and Correlates to Disease Progression in the ADNI Population", is focused on the
results of analyses performed using imaging of glucose metabolism on participants in the
Alzheimers Disease Neuroimaging Initiative (ADNI).
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and
premier conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference
will take place from July 11 - 16 in Vienna, Austria.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance
imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the
ADNI website.
Abiant, Inc.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers
of drug effects and disease progression. The imaging information, which includes biochemical,
functional, and structural measurements, is intended to accelerate or reduce risk of decision making
in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,”
"achieve," and "enable." There are a number of important factors that could cause Abiant's results to
differ materially from those indicated by these forward-looking statements.
 |
 |